1. Pfizer has not conducted gain of function or directed evolution research in the development of the Pfizer-BioNTech COVID-19 vaccine.
2. Pfizer undertakes in vitro work to identify potential resistance mutations to nirmatrelvir, one of PAXLOVID’s two components.
3. Pfizer-BioNTech COVID-19 Vaccine and Pfizer-BioNTech COVID-19 Vaccine, Bivalent are FDA authorized under Emergency Use Authorization (EUA) for use in individuals 6 months to 4 years of age.
The article is written by a representative from Pfizer, which could lead to bias in the reporting as it is likely that they will be presenting their own company's research and products in a positive light. The article does not provide any evidence for the claims made, such as data from studies or trials that have been conducted on their products or research methods. Additionally, there is no mention of any potential risks associated with their products or research methods, which could be seen as a form of promotional content. Furthermore, there is no exploration of counterarguments or other points of view regarding their research methods or products, making it appear one-sided and potentially biased. Finally, there is no mention of any ethical considerations related to their research methods or products, which could be seen as an oversight on the part of the author.